Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
US group hopes EyeBio will refill its pipeline with treatments targeting causes of blindness
Full Article
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
FT.com
0 shares
1 views